Vasobrail has a vasodilating effect, without affecting the systemic blood pressure. The appointment of Vasobral to patients with hypertension does not exclude the need for antihypertensive drugs.
Contained in the preparation caffeine can cause sleep disturbance, tachycardia.
It should avoid taking the drug on an empty stomach.
In patients taking dihydroergocryptine, especially at high doses and for a long time, sometimes the development of effusion into the pericardial cavity and the pleural cavity was reported, as well as the development of pleural and pulmonary fibrosis and constrictive pericarditis. Patients with unexplained pleuropulmonary disorders should be examined and the issue of discontinuing treatment with dihydroergocryptine should be considered.
There have been reports of rare cases of retroperitoneal fibrosis, especially when high doses are used and with prolonged treatment with dihydroergocryptin. In order to diagnose retroperitoneal fibrosis at a reversible stage, such patients should be regularly observed for clinical signs of retroperitoneal fibrosis (back pain, edema of the lower extremities, renal failure). When diagnosing or suspected fibrotic changes in the retroperitoneal space, treatment with dihydroergocryptin should be discontinued.
Athletes should be warned that this drug contains a substance that can cause a positive reaction in tests conducted during doping control.